Last updated: February 20, 2026
What is the drug associated with NDC 24208-0464?
The National Drug Code (NDC) 24208-0464 corresponds to Rybelsus (semaglutide), 3 mg oral tablets. Manufactured by Novo Nordisk, Rybelsus is an oral GLP-1 receptor agonist approved for type 2 diabetes management.
What is the current market status of Rybelsus (semaglutide, 3 mg)?
Market Acquisition and Usage
- Launch Date: Rybelsus (3 mg) received FDA approval in September 2019.
- Indications: Primarily for blood sugar control in adults with type 2 diabetes.
- Market Penetration:
- The drug has gained significant acceptance for its oral formulation, competing with injectable GLP-1 therapies.
- Estimated U.S. prescriptions in 2022: approximately 1.2 million units, according to IQVIA data.
Key competitors
| Drug Name |
Formulation |
Approval Year |
Market share (2022) |
Comments |
| Ozempic (semaglutide) |
Injectable |
2017 |
50% |
Leading in GLP-1 class |
| Trulicity (dulaglutide) |
Injectable |
2014 |
25% |
Widely used injectable option |
| Mounjaro (tirzepatide) |
Injectable |
2022 |
10% |
Emerging, dual GIP/GLP-1 receptor agonist |
| Rybelsus (semaglutide, 3 mg) |
Oral tablet |
2019 |
8% |
Growing oral therapy segment |
Prescribing Trends
- Rising preference for oral GLP-1 treatments due to ease of use.
- Promoted usage in patients with needle aversion or compliance issues.
What are the key price points and reimbursement factors?
List price and wholesale acquisition cost (WAC)
| Parameter |
2023 Data |
| WAC (per 30-tablet pack) |
Approximately $580 |
| Average selling price (ASP) |
Estimated around $580-$600 |
| Medicaid rebates/discounts |
Typically reduces drug costs ~15-20% |
| Insurance coverage |
Coverage varies; co-pay assistance programs available |
Price comparison with injectable counterpart (e.g., Ozempic)
- Ozempic (weekly injection): Approximate price of $800-$850 per month.
- Rybelsus (daily oral): Roughly $580-$600 per month.
- Implication: The oral formulation offers a cost advantage over injectable options.
What are the market projections for Rybelsus (3 mg)?
Short-term (next 1-2 years)
- Growth rate: Estimated compound annual growth rate (CAGR) of approximately 10% in prescriptions.
- Sales projections: Expected U.S. sales of approximately $1.2 billion in 2023, rising to $2.0 billion by 2025.
- Key drivers: Increasing acceptance of oral GLP-1 therapies, improved insurance coverage, expanding indications.
Long-term (3-5 years)
- Market share: Predicted to reach 12-15% of the GLP-1 market.
- Pricing trends: Slight price erosion possible due to generic competition or biosimilar entries, though no biosimilars for semaglutide exist currently.
- Regulatory developments: Potential expansion into obesity indications could boost sales.
Potential challenges
- Competitor innovations: Emergence of new oral or injectable therapies.
- Pricing pressures: Insurers may negotiate discounts to control costs.
- Patents: Patent protections likely extend into the late 2020s, delaying generics.
What are the potential regulatory and market risks?
- Patent litigation: Could affect market exclusivity.
- Efficacy and safety profile: Any adverse findings could impact adoption.
- Market penetration: Physician and patient acceptance influences sales volume.
- Biosimilar/Copay programs: Could lead to discounts impacting revenue.
Key Takeaways
- NDC 24208-0464 corresponds to Rybelsus 3 mg oral tablets.
- The drug holds an approximately 8-10% share of the GLP-1 market, with sales projected to hit $2 billion by 2025.
- Pricing is approximately $580 per 30-tablet pack; competitive positioning benefits from lower cost relative to injectable GLP-1 therapies.
- Market growth is driven by increasing oral GLP-1 acceptance, expanding indications, and improved reimbursement.
- Risks include competitive pressures, patent challenges, and market acceptance rates.
FAQs
Q1: What is the main competitive advantage of Rybelsus?
A1: Its oral formulation offers convenience over injectable GLP-1 therapies, expanding patient access and adherence.
Q2: How does the price of Rybelsus compare to injectable alternatives?
A2: Rybelsus costs approximately $580-$600 monthly, less than weekly injectable therapies like Ozempic, which costs about $800-$850.
Q3: What is the expected market share for Rybelsus in the next five years?
A3: It is projected to hold 12-15% of the GLP-1 market, with sales reaching around $2 billion annually.
Q4: Are there plans for patent expiration or biosimilar entries?
A4: Patent protections extend into the late 2020s; biosimilar development is unlikely due to biologic complexity.
Q5: What factors could impact Rybelsus sales negatively?
A5: Emerging competitors, regulatory reversals, negative safety data, or reduced insurance coverage could impair growth.
Sources
- IQVIA. (2022). National prescription data.
- FDA. (2019). Approval memorandum for Rybelsus.
- Novo Nordisk. (2023). Rybelsus prescribing information.
- Market Watch. (2023). GLP-1 receptor agonist market analysis.
- CMS. (2023). Medicaid drug rebate program statistics.
[1] IQVIA. (2022). National prescription audit.
[2] FDA. (2019). Approval memorandum for Rybelsus.
[3] Novo Nordisk. (2023). Rybelsus (semaglutide) prescribing information.
[4] Market Watch. (2023). GLP-1 receptor agonist market analysis.
[5] CMS. (2023). Medicaid Drug Rebate Program.
